Overall Score

Revenue Model

Kura Oncology remains a single-product biotech with no recurring revenue stream, so monetization still depends on clinical and regulatory milestones.

TTM revenue per share is only 0.87 while price-to-sales is 12.48, indicating the market is still valuing future pipeline potential rather than current sales.

Profitability

TTM margins remain deeply negative, with operating margin at -4.12 and net profit margin at -3.84, reflecting ongoing operating losses.

Return metrics are still very weak, with ROE at -2.07 and ROIC at -0.67, showing the business is not yet generating economic returns.

Balance Sheet

Liquidity remains solid with a current ratio of 4.73 and quick ratio of 4.71, giving the company ample near-term flexibility.

Leverage is still modest, with debt-to-equity at 0.50 and debt-to-assets at 0.04, while cash per share of 5.84 remains well above book value per share of 0.55.

Cash Flow

Cash generation remains negative, with operating cash flow per share at -1.26 and free cash flow per share at -1.32.

Free cash flow yield is still negative at -12.18% and EV/FCF remains negative, confirming the company is burning cash rather than producing it.

Operating Efficiency

Gross margin is still very high at 94.73%, but that has not translated into operating profitability because R&D to revenue is 3.36 and SG&A to revenue is 1.75.

Working-capital efficiency remains mixed, with a cash conversion cycle of 52.98 days and elevated inventory and payables days reflecting a development-stage operating profile.